COMMUNIQUÉS West-GlobeNewswire

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
10/08/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart [...]
Kraig Biocraft Laboratories CEO Kim Thompson Publishes Thought Leadership Article on the Next Chapter of Authored Biology in Biocompare
10/08/2026
Byline Article Introduces "Authored Biology" Framework and Draws on Kraig Labs' Spider Silk Journey to Chart the Future of Biology-Enabled Manufacturing ANN ARBOR, Mich., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft [...]
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program [...]
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
10/08/2026
Acquisition adds ABS-011, an investigational Phase 2b gallium-68-labeled PET radiodiagnostic tracer targeting HER2 Transaction strengthens Curium radiodiagnostic capabilities and oncology footprint, including in breast [...]
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
10/08/2026
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 [...]
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
10/08/2026
Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin ® -C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients [...]
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
10/08/2026
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 [...]
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and [...]
BrewDog Claims London's Summer Park Season with ‘Park IPA’
10/08/2026
Punk IPA becomes “Park IPA” throughout August as BrewDog celebrates one of London’s most iconic summer traditions – great beer, great friends and sunny afternoons in the park. ELTON, United Kingdom, Aug. 10, 2026 (GLOBE [...]
Internationally Recognized Johns Hopkins Oncologist Dr. Stephen J. Noga Joins Immunocine as Chief Medical Officer
10/08/2026
Veteran Physician-Scientist and Cellular Therapy Expert to Help Advance the Future of Personalized Cancer Immunotherapy HOUSTON, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Immunocine Cancer Center today announced the [...]
Reacta Healthcare Announces the Appointment of Iedena Lima as Head of Research and Development
10/08/2026
Extensive Pharma and Medtech Sector Experience Strengthens Senior Leadership to Support Growth and Strategic Expansion DEESIDE, United Kingdom, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer [...]
Zelluna ASA: New share capital registered
10/08/2026
Oslo, 10 August 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the "Company") on 4 August 2026 regarding the Board of Directors resolution to issue 446,752 new shares to Inven2 AS [...]
From a Simple Idea to Thousands of Smiles: Teddy Bears On Call Celebrates 10 Years of Comforting Children in Crisis Through Its 3rd Annual Charity Golf Tournament
10/08/2026
STATEN ISLAND, N.Y, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Teddy Bears On Call, Inc. (TBOC), a volunteer 501(c)(3) nonprofit organization dedicated to comforting children receiving emergency medical treatment, will host [...]
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
10/08/2026
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creation Transaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050 [...]
Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities
10/08/2026
Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities COPENHAGEN, Denmark, August 10 – Novonesis has signed an agreement with the intent to acquire MicroBioGen, an Australian biotechnology [...]
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
10/08/2026
ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address [...]
AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
10/08/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 14.2 MILLION PRIVATE PLACEMENT, PRIMARILY SUSBCRIBED BY LONG TERM INVESTOR AB SCIENCE CASH POSITION IS AROUND EUR 23 MILLION AFTER THIS PRIVATE [...]
AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros
10/08/2026
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE DE 14,2 MILLIONS D’EUROS, SOUSCRIT PRINCIPALEMENT PAR UN INVESTISSEUR DE LONG TERME LA TRESORERIE D’AB SCIENCE S’ELEVE A ENVIRON 23 MILLIONS D’EUROS [...]
Kylo Peptides Expands Research Catalog to 36 Compounds as Peptide Science Enters a Record Growth Cycle
10/08/2026
US research-peptide supplier scales its catalog against a market that analysts value between $47 billion and $141 billion, as peptides hold near 10% of new FDA drug approvals and GLP-1 use among American adults doubles [...]

Pages